

Farmeconomia. Health economics and therapeutic pathways 2019; 20(1): 51
<https://doi.org/10.7175/fe.v20i1.1438>

Corrigendum: Treatments of Advanced Non-Small Cell Lung Cancer (NSCLC) in an Italian Center: Drug Utilization and the Treatment Costs of Innovative Drugs



ORIGINAL
RESEARCH

Piantedosi F, Cerisoli R, Battiloro C, Andreozzi F, Vitiello F, Gilli M, De Marino V, Letizia A, Bianco A, Caprice I, Savoia A, Cristinziano A, Smeraglio G, Rocco D. Treatments of Advanced Non-Small Cell Lung Cancer (NSCLC) in an Italian Center: Drug Utilization and the Treatment Costs of Innovative Drugs. *Farmeconomia. Health economics and therapeutic pathways* 2019; 20(1): 27-41; <https://doi.org/10.7175/fe.v20i1.1376>

There was an error in Discussion section at page 36 in this article by Piantedosi et al. [*Farmeconomia. Health economics and therapeutic pathways* 2019; 20(1): 27-41; <https://doi.org/10.7175/fe.v20i1.1376>]. The online version has been corrected on June 5, 2019, as shown below.

The phrase «The final treatment costs will be at net of negotiation settlement and credit note» has been replaced by «Drug expenditure was calculated as the price payed by the local pharmacy per single dose multiplied by the actual quantity administered. Credit notes and national management agreement are not included».

We apologize for any inconvenience caused.

Published: 5 June 2019

